Emergency / crisis support: /emergency
If belimumab has been declined, nephritis treatment is creating unexpected costs, or your monitoring tests are being refused — here are the steps to take.
In a Severe Flare Right Now
If you are experiencing an acute severe SLE flare requiring hospitalisation — neuropsychiatric SLE, severe cytopenias, rapidly progressive nephritis, serositis — acute SLE flares are PMB-covered. Your scheme cannot refuse emergency hospitalisation.
Call your scheme's 24-hour hospitalisation line. Request PMB emergency authorisation for SLE flare. Ensure your rheumatologist is the supervising specialist on the admission — this is important for correct claim classification. If the scheme refuses emergency authorisation, go to hospital regardless and obtain retrospective authorisation. Do not delay care for an administrative dispute.
Common SLE Financial Crises
1. Belimumab exceptional-needs declined. 2. CDL medications charged to MSA instead of CDL benefit. 3. Cyclophosphamide processed incorrectly through oncology sub-limit. 4. Monitoring tests refused under CDL benefit. 5. Nephritis costs (nephrology + rheumatology co-management) generating unexpectedly high shortfalls.
If Belimumab Was Declined
Step 1: Request written decline with clinical reasoning.
Step 2: Enhanced motivation — include SLEDAI-2K ≥ 8, current anti-dsDNA level, complement C3/C4, evidence of prior immunosuppressant failure at adequate dose and duration, steroid burden, and BLISS-52/BLISS-76 trial references.
Step 3: Request a peer-to-peer review between your rheumatologist and the scheme's medical advisor.
Step 4: Formal internal appeal if the peer-to-peer does not resolve it.
Step 5: CMS complaint if the internal appeal fails. The CMS has adjudicated on biologics for autoimmune conditions; a well-documented application has a reasonable prospect.
If Cyclophosphamide Is Being Applied to Your Oncology Sub-Limit
Cyclophosphamide for lupus nephritis is not cancer treatment. It should be processed under your SLE/CDL/PMB benefit — not under an oncology sub-limit. If the scheme routes it to oncology:
Write to case management: "Cyclophosphamide is being administered for the treatment of Class III/IV lupus nephritis, a direct complication of the patient's CDL-registered SLE (ICD-10: M32). This is not an oncological condition. The claims should be processed under the CDL/PMB benefit for SLE, not the oncology sub-limit."
Include your rheumatologist's letter stating the indication.
If Monitoring Tests Are Being Refused
Laboratory monitoring (FBC, renal function, urine PCR, anti-dsDNA, complement) is clinically necessary for safe management of SLE and immunosuppressant therapy. The scheme's CDL obligation includes "diagnosis, treatment, and care" — ongoing safety monitoring is care.
Write to chronic benefits requesting that monitoring tests prescribed by your treating rheumatologist for CDL-registered SLE be funded under the CDL benefit. If the scheme refuses, escalate to the CMS citing the CDL "care" obligation.
Nephritis Co-Management: Managing Double Specialist Costs
When lupus nephritis is active and both a rheumatologist and a nephrologist are consulting, specialist shortfalls double. Confirm both specialists are billing and that your gap cover covers both. Submit shortfalls to your gap cover provider after each visit. If shortfalls are accumulating toward the OPL (~R220,000/year), prioritise surgical and procedure-based claims for gap cover and arrange payment plans with the consulting specialists for ongoing consultation shortfalls.
The Rheumatologist's Role in Financial Navigation
Your rheumatologist is your most important ally in scheme disputes. Most rheumatologists in SA private practice are familiar with the CDL and exceptional-needs landscape for SLE. Before submitting any appeal or CMS complaint, confirm with your rheumatologist that they are prepared to support the application in writing and, if needed, by peer-to-peer clinical review. A scheme that resists a written clinical challenge from a consultant rheumatologist citing published guidelines and SLEDAI scores has a weak position.
Keep a copy of every piece of scheme correspondence — every decline, every approval, every case manager note. This documentation chain is essential if the dispute reaches the CMS.
Document every interaction with your scheme in writing. Email confirmation of every phone call. The CMS requires a documented trail of internal disputes before escalating — schemes that have not received a written dispute cannot be held to account at CMS level. The threshold from 'I called and they said no' to 'I have written evidence of a systematic refusal of a CDL obligation' is the difference between a case the CMS can act on and one it cannot.
Triage Table
| Situation | Priority | Action |
|---|---|---|
| Severe flare — hospitalisation | Urgent | PMB emergency auth; rheumatologist as supervising specialist |
| Belimumab declined | High | Enhanced motivation + peer-to-peer + CMS |
| CDL meds on MSA | High | CDL registration + reprocessing |
| Cyclophosphamide on oncology sub-limit | High | Written reclassification to CDL/PMB benefit |
| Monitoring tests refused | Medium | CDL "care" obligation letter |
| Double specialist (nephritis) shortfall | Medium | Gap cover for both; payment plans for balance |
Escalation Contacts
Council for Medical Schemes (CMS): 0861 123 267 | www.medicalschemes.org.za Lupus SA: www.lupussa.org AURA Emergency: /emergency
Talk to Eldon
Get urgent help with your cover situation →
This page is general information about medical schemes. It is not medical advice: speak to a healthcare professional about your own treatment. Medical aid and gap cover advice is given by Eldon de Waal, a Supervised Representative of Approach Administration (FSP 23579).